216 related articles for article (PubMed ID: 34324636)
1. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study.
Savitz A; Wajs E; Zhang Y; Xu H; Etropolski M; Thase ME; Drevets WC
Int J Neuropsychopharmacol; 2021 Dec; 24(12):965-976. PubMed ID: 34324636
[TBL] [Abstract][Full Text] [Related]
2. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
4. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
Recourt K; de Boer P; Zuiker R; Luthringer R; Kent J; van der Ark P; Van Hove I; van Gerven J; Jacobs G; van Nueten L; Drevets W
Transl Psychiatry; 2019 Sep; 9(1):216. PubMed ID: 31481683
[TBL] [Abstract][Full Text] [Related]
5. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
[TBL] [Abstract][Full Text] [Related]
6. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
[TBL] [Abstract][Full Text] [Related]
9. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.
Bauer M; Pretorius HW; Constant EL; Earley WR; Szamosi J; Brecher M
J Clin Psychiatry; 2009 Apr; 70(4):540-9. PubMed ID: 19358791
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
11. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA
J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554
[TBL] [Abstract][Full Text] [Related]
13. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
16. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
17. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
20. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
